Free Access
Med Sci (Paris)
Volume 34, Number 5, Mai 2018
Page(s) 391 - 394
Section Le Magazine
Published online 13 June 2018
  1. Chung RT, Baumert TF. Curing chronic hepatitis C: the arc of a medical triumph. N Engl J Med 2014 ; 370 : 1576–1578. [Google Scholar]
  2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012 ; 142 : 1264–1273.e1. [CrossRef] [PubMed] [Google Scholar]
  3. Mailly L, Zeisel MB, Baumert TF. Enfermé dehors ! Traitement de l’hépatite C chronique par un inhibiteur d’entrée. Med Sci (Paris) 2015 ; 31 : 1075–1077. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Baumert TF, Juhling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017 ; 15 : 52. [CrossRef] [PubMed] [Google Scholar]
  5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011 ; 365 : 1118–1127. [Google Scholar]
  6. Hoshida Y, Fuchs BC, Bardeesy N, et al. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol 2014 ; 61 : S79–S90. [CrossRef] [PubMed] [Google Scholar]
  7. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology 2016 ; 64 : 130–137. [CrossRef] [PubMed] [Google Scholar]
  8. Toyoda H, Kumada T, Tada T. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology 2016 ; 64 : 1818–1819. [CrossRef] [PubMed] [Google Scholar]
  9. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012 ; 308 : 2584–2593. [CrossRef] [PubMed] [Google Scholar]
  10. European association for the study of the liver; European organisation for research and treatment of cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 : 908–43. [Google Scholar]
  11. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016 ; 65 : 727–733. [CrossRef] [PubMed] [Google Scholar]
  12. Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016 ; 65 : 719–726. [CrossRef] [PubMed] [Google Scholar]
  13. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016 ; 65 : 734–740. [CrossRef] [PubMed] [Google Scholar]
  14. Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017 ; 153 : 996–1005.e1. [CrossRef] [PubMed] [Google Scholar]
  15. van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017 ; 66 : 485–493. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.